Unpicking the Combination Lock for Mutant BRAF and RAS Melanomas

被引：4

作者：

Al-Lazikani, Bissan ^{[1
]}

Workman, Paul ^{[1
]}

机构：

[1] Inst Canc Res, Canc Res UK Canc Therapeut Unit, London, England

来源：

CANCER DISCOVERY | 2013年 / 3卷 / 01期

关键词：

CANCER; THERAPY; STRATEGIES; GENOME; ERA;

D O I：

10.1158/2159-8290.CD-12-0520

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Large-scale, unbiased combinatorial drug screening has been used to identify effective genotype-selective therapeutic combinations that show promising activity in preclinical models of mutant BRAF and RAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib. Cancer Discov; 3( 1); 14-9. (C) 2012 AACR.

引用

页码：14 / 19

页数：6

共 14 条

[1] Combinatorial drug therapy for cancer in the post-genomic era [J].

Al-Lazikani, Bissan ;

Banerji, Udai ;

Workman, Paul .

NATURE BIOTECHNOLOGY, 2012, 30 (07) :679-691

[2] A Missing Link in Genotype-Directed Cancer Therapy [J].

Bernards, Rene .

CELL, 2012, 151 (03) :465-468

[3] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[4] Circumventing Cancer Drug Resistance in the Era of Personalized Medicine [J].

Garraway, Levi A. ;

Jaenne, Pasi A. .

CANCER DISCOVERY, 2012, 2 (03) :214-226

[5] PERSPECTIVE Finding cancer's first principles [J].

Gatenby, Robert .

NATURE, 2012, 491 (7425) :S55-S55

[6] Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF [J].

Heidorn, Sonja J. ;

Milagre, Carla ;

Whittaker, Steven ;

Nourry, Arnaud ;

Niculescu-Duvas, Ion ;

Dhomen, Nathalie ;

Hussain, Jahan ;

Reis-Filho, Jorge S. ;

Springer, Caroline J. ;

Pritchard, Catrin ;

Marais, Richard .

CELL, 2010, 140 (02) :209-221

[7] Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening [J].

Held, Matthew A. ;

Langdon, Casey G. ;

Platt, James T. ;

Graham-Steed, Tisheeka ;

Liu, Zongzhi ;

Chakraborty, Ashok ;

Bacchiocchi, Antonella ;

Koo, Andrew ;

Haskins, Jonathan W. ;

Bosenberg, Marcus W. ;

Stern, David F. .

CANCER DISCOVERY, 2013, 3 (01) :52-67

[8] The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner [J].

Joseph, Eric W. ;

Pratilas, Christine A. ;

Poulikakos, Poulikos I. ;

Tadi, Madhavi ;

Wang, Weiqing ;

Taylor, Barry S. ;

Halilovic, Ensar ;

Persaud, Yogindra ;

Xing, Feng ;

Viale, Agnes ;

Tsai, James ;

Chapman, Paul B. ;

Bollag, Gideon ;

Solit, David B. ;

Rosen, Neal .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (33) :14903-14908

[9] Targeting Mutant BRAF in Melanoma Current Status and Future Development of Combination Therapy Strategies [J].

Kudchadkar, Ragini ;

Paraiso, Kim H. T. ;

Smalley, Keiran S. M. .

CANCER JOURNAL, 2012, 18 (02) :124-131

[10] Initial impact of the sequencing of the human genome [J].

Lander, Eric S. .

NATURE, 2011, 470 (7333) :187-197

← 1 2 →